These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 32143905)

  • 1. Dissecting the spatial heterogeneity of different immune cell subsets in non-small cell lung cancer.
    Jurmeister P; von Laffert M; Jöhrens K
    Pathol Res Pract; 2020 May; 216(5):152904. PubMed ID: 32143905
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multispectral imaging for quantitative and compartment-specific immune infiltrates reveals distinct immune profiles that classify lung cancer patients.
    Mezheyeuski A; Bergsland CH; Backman M; Djureinovic D; Sjöblom T; Bruun J; Micke P
    J Pathol; 2018 Apr; 244(4):421-431. PubMed ID: 29282718
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of neoadjuvant chemotherapy on the immune microenvironment in non-small cell lung carcinomas as determined by multiplex immunofluorescence and image analysis approaches.
    Parra ER; Villalobos P; Behrens C; Jiang M; Pataer A; Swisher SG; William WN; Zhang J; Lee J; Cascone T; Heymach JV; Forget MA; Haymaker C; Bernatchez C; Kalhor N; Weissferdt A; Moran C; Zhang J; Vaporciyan A; Gibbons DL; Sepesi B; Wistuba II
    J Immunother Cancer; 2018 Jun; 6(1):48. PubMed ID: 29871672
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Functional Heterogeneity of CD4
    Oja AE; Piet B; van der Zwan D; Blaauwgeers H; Mensink M; de Kivit S; Borst J; Nolte MA; van Lier RAW; Stark R; Hombrink P
    Front Immunol; 2018; 9():2654. PubMed ID: 30505306
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impaired Tumor-Infiltrating T Cells in Patients with Chronic Obstructive Pulmonary Disease Impact Lung Cancer Response to PD-1 Blockade.
    Biton J; Ouakrim H; Dechartres A; Alifano M; Mansuet-Lupo A; Si H; Halpin R; Creasy T; Bantsimba-Malanda C; Arrondeau J; Goldwasser F; Boudou-Rouquette P; Fournel L; Roche N; Burgel PR; Goc J; Devi-Marulkar P; Germain C; Dieu-Nosjean MC; Cremer I; Herbst R; Damotte D
    Am J Respir Crit Care Med; 2018 Oct; 198(7):928-940. PubMed ID: 29518341
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic effect of epithelial and stromal lymphocyte infiltration in non-small cell lung cancer.
    Al-Shibli KI; Donnem T; Al-Saad S; Persson M; Bremnes RM; Busund LT
    Clin Cancer Res; 2008 Aug; 14(16):5220-7. PubMed ID: 18698040
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical significance of PD-L1-positive cancer-associated fibroblasts in pN0M0 non-small cell lung cancer.
    Teramoto K; Igarashi T; Kataoka Y; Ishida M; Hanaoka J; Sumimoto H; Daigo Y
    Lung Cancer; 2019 Nov; 137():56-63. PubMed ID: 31546072
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of the immune microenvironment in resected non-small cell lung cancer: the prognostic value of different T lymphocyte markers.
    Usó M; Jantus-Lewintre E; Bremnes RM; Calabuig S; Blasco A; Pastor E; Borreda I; Molina-Pinelo S; Paz-Ares L; Guijarro R; Martorell M; Forteza J; Camps C; Sirera R
    Oncotarget; 2016 Aug; 7(33):52849-52861. PubMed ID: 27463005
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stromal PD-L1-Positive Regulatory T cells and PD-1-Positive CD8-Positive T cells Define the Response of Different Subsets of Non-Small Cell Lung Cancer to PD-1/PD-L1 Blockade Immunotherapy.
    Wu SP; Liao RQ; Tu HY; Wang WJ; Dong ZY; Huang SM; Guo WB; Gou LY; Sun HW; Zhang Q; Xie Z; Yan LX; Su J; Yang JJ; Zhong WZ; Zhang XC; Wu YL
    J Thorac Oncol; 2018 Apr; 13(4):521-532. PubMed ID: 29269008
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Determination of poor prognostic immune features of tumour microenvironment in non-smoking patients with lung adenocarcinoma.
    Kinoshita T; Kudo-Saito C; Muramatsu R; Fujita T; Saito M; Nagumo H; Sakurai T; Noji S; Takahata E; Yaguchi T; Tsukamoto N; Hayashi Y; Kaseda K; Kamiyama I; Ohtsuka T; Tomizawa K; Shimoji M; Mitsudomi T; Asamura H; Kawakami Y
    Eur J Cancer; 2017 Nov; 86():15-27. PubMed ID: 28950145
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High OX-40 expression in the tumor immune infiltrate is a favorable prognostic factor of overall survival in non-small cell lung cancer.
    Massarelli E; Lam VK; Parra ER; Rodriguez-Canales J; Behrens C; Diao L; Wang J; Blando J; Byers LA; Yanamandra N; Brett S; Morley P; Sharma P; Allison J; Wistuba II; Heymach JV
    J Immunother Cancer; 2019 Dec; 7(1):351. PubMed ID: 31843013
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Morphological Evaluation of Tumor-Infiltrating Lymphocytes (TILs) to Investigate Invasive Breast Cancer Immunogenicity, Reveal Lymphocytic Networks and Help Relapse Prediction: A Retrospective Study.
    Romagnoli G; Wiedermann M; Hübner F; Wenners A; Mathiak M; Röcken C; Maass N; Klapper W; Alkatout I
    Int J Mol Sci; 2017 Sep; 18(9):. PubMed ID: 28885584
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Infiltration of NK and plasma cells is associated with a distinct immune subset in non-small cell lung cancer.
    Backman M; La Fleur L; Kurppa P; Djureinovic D; Elfving H; Brunnström H; Mattsson JSM; Lindberg A; Pontén V; Eltahir M; Mangsbo S; Gulyas M; Isaksson J; Jirström K; Kärre K; Leandersson K; Mezheyeuski A; Pontén F; Strell C; Lindskog C; Botling J; Micke P
    J Pathol; 2021 Nov; 255(3):243-256. PubMed ID: 34339045
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune Cell Composition in Human Non-small Cell Lung Cancer.
    Stankovic B; Bjørhovde HAK; Skarshaug R; Aamodt H; Frafjord A; Müller E; Hammarström C; Beraki K; Bækkevold ES; Woldbæk PR; Helland Å; Brustugun OT; Øynebråten I; Corthay A
    Front Immunol; 2018; 9():3101. PubMed ID: 30774636
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metastatic spread in patients with non-small cell lung cancer is associated with a reduced density of tumor-infiltrating T cells.
    Müller P; Rothschild SI; Arnold W; Hirschmann P; Horvath L; Bubendorf L; Savic S; Zippelius A
    Cancer Immunol Immunother; 2016 Jan; 65(1):1-11. PubMed ID: 26541588
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Composition of the immune microenvironment differs between carcinomas metastatic to the lungs and primary lung carcinomas.
    Senarathne W; Vranic S; Xiu J; Rose I; Gates P; Gatalica Z
    Ann Diagn Pathol; 2018 Apr; 33():62-68. PubMed ID: 29566951
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune Microenvironment Differences Between Squamous and Non-squamous Non-small-cell Lung Cancer and Their Influence on the Prognosis.
    Meng X; Gao Y; Yang L; Jing H; Teng F; Huang Z; Xing L
    Clin Lung Cancer; 2019 Jan; 20(1):48-58. PubMed ID: 30341017
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Variants in Epithelial-Mesenchymal Transition and Immune Checkpoint Genes Are Associated With Immune Cell Profiles and Predict Survival in Non-Small Cell Lung Cancer.
    Parra ER; Jiang M; Machado-Rugolo J; Yaegashi LB; Prieto T; Farhat C; de Sá VK; Nagai MA; de Lima VCC; Takagaki T; Terra R; Fabro AT; Capelozzi VL
    Arch Pathol Lab Med; 2020 Oct; 144(10):1234-1244. PubMed ID: 32150457
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessing PDL-1 and PD-1 in Non-Small Cell Lung Cancer: A Novel Immunoscore Approach.
    Paulsen EE; Kilvaer TK; Khanehkenari MR; Al-Saad S; Hald SM; Andersen S; Richardsen E; Ness N; Busund LT; Bremnes RM; Donnem T
    Clin Lung Cancer; 2017 Mar; 18(2):220-233.e8. PubMed ID: 27816392
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immuno-profiling and cellular spatial analysis using five immune oncology multiplex immunofluorescence panels for paraffin tumor tissue.
    Parra ER; Ferrufino-Schmidt MC; Tamegnon A; Zhang J; Solis L; Jiang M; Ibarguen H; Haymaker C; Lee JJ; Bernatchez C; Wistuba II
    Sci Rep; 2021 Apr; 11(1):8511. PubMed ID: 33875760
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.